| Předmět: |
|
| Zdroj: |
Medical Letter on the CDC & FDA; 12/17/2023, p3760-3760, 1p |
| Abstrakt: |
A patent application has been published online for an oral delayed burst formulation of low-dose naltrexone (LDN) that aims to treat fibromyalgia and Long Covid. The application highlights the need for a LDN formulation that avoids the side effects of opioid antagonists and discusses the symptoms and challenges associated with these conditions. The proposed formulation consists of a core containing naltrexone and other excipients, a delayed release layer, and a subcoat layer. It is designed to be taken shortly before sleep. The patent application provides detailed information on the composition and administration methods of the formulation. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
